You are on page 1of 1

January 22, 2015

Carl Elliott, MD, PhD
Professor
Center for Bioethics
N504 Boynton
410 Church Street
Minneapolis MN 55455
Dear Professor Elliott,
I am writing in response to your letter dated January 18, 2015, to provide you with information regarding the status of the
IRB Investigation Panel’s review of your complaint and allegations of non-compliance associated with the research
conducted by Dr. Stephen Olson titled “An Open-Label, Flexible-Dose, Long-Term Safety and Efficacy Study of Bifeprunox in
the Treatment of Schizophrenia, Protocol S1543002”.
The IRB Investigation Panel has completed its work and the IRB has prepared an investigation report. However, this matter
is not yet concluded as the University has decided to engage an outside entity to further evaluate the allegations and IRB
findings.
You will be informed once there is a final decision on this matter.
In the meantime, I wish to thank you for your continued patience as evaluation of this important matter continues.
Sincerely,

Debra
Dykhuis

Digitally signed by Debra Dykhuis
DN: c=US, st=Minnesota,
l=Minneapolis, ou=Human
Research Protection Program,
email=dykhu001@umn.edu,
o=University of Minnesota,
cn=Debra Dykhuis
Date: 2015.01.22 14:51:55 -06'00'

Debra A. Dykhuis
Executive Director
c:

Brian Herman
Susan Berry
J. Michael Oakes